Kindeva Drug Delivery: Company Profile
Background
Kindeva Drug Delivery is a global Contract Development and Manufacturing Organization (CDMO) specializing in drug-device combination products. The company offers comprehensive services across various drug delivery formats, including pulmonary, nasal, injectable, transdermal, and intradermal therapies. With a legacy spanning over a century, Kindeva has been instrumental in developing and commercializing complex drug delivery systems, such as the first metered-dose inhaler (MDI) and the first drug-in-adhesive transdermal patch.
Key Strategic Focus
Kindeva's strategic focus encompasses:
- Core Objectives: To provide end-to-end solutions in drug delivery, facilitating the efficient development and manufacturing of complex drug-device combination products.
- Areas of Specialization: Expertise in pulmonary, nasal, injectable, transdermal, and intradermal drug delivery systems.
- Key Technologies Utilized: Advanced technologies in inhalation, transdermal delivery, microneedles, and connected drug delivery systems.
- Primary Markets Targeted: Pharmaceutical and biotechnology sectors, focusing on both large multinational corporations and emerging biotech firms seeking specialized drug delivery solutions.
Financials and Funding
Kindeva was established in 2020 following the acquisition of 3M's Drug Delivery Systems business by Altaris Capital Partners for $650 million. The company has since secured additional funding, with a total of $46.84 million raised, including a $41.84 million round three years ago. The capital has been utilized to expand manufacturing capabilities, enhance research and development efforts, and support strategic acquisitions.
Pipeline Development
Kindeva's pipeline includes a diverse range of drug-device combination products across various stages of development:
- Pulmonary and Nasal Therapies: Development of low-GWP inhalers, with plans to open a commercial-scale green propellant line.
- Injectable Products: Expansion of aseptic fill-finish capabilities, including a new 155,000-square-foot facility in St. Louis, MO, operational by mid-2024.
- Transdermal and Intradermal Systems: Ongoing development of microneedle-based drug delivery platforms for various therapeutic areas.
Technological Platform and Innovation
Kindeva distinguishes itself through:
- Proprietary Technologies: Development of the first metered-dose inhaler (MDI) and the first drug-in-adhesive transdermal patch.
- Significant Scientific Methods: Advanced formulation techniques for inhalation and transdermal delivery, as well as microneedle technology for intradermal drug delivery.
Leadership Team and Changes
The leadership team comprises:
- Milton Boyer: CEO of the combined entity following the merger with Meridian Medical Technologies.
- Aaron Mann: Former CEO of Kindeva prior to the merger, with extensive experience in drug delivery systems.
- Keith Ung: CEO and Co-founder of iPharma Labs, which was acquired by Kindeva in 2022.
In November 2022, Kindeva announced its intention to merge with Meridian Medical Technologies, a leader in autoinjector technology. The merger was completed in December 2022, with Milton Boyer, formerly CEO of Meridian, assuming the role of CEO of the combined company.
Competitor Profile
Market Insights and Dynamics
The global CDMO market was valued at over $150 billion in 2024, with the pharmaceutical equipment market approximately at $11 billion. The industry is characterized by rapid technological advancements and increasing demand for complex drug-device combination products.
Competitor Analysis
Key competitors include:
- Catalent: A major CDMO with a broad range of services, including inhaled drug delivery and sterile manufacturing.
- Lonza: Offers a wide array of drug product services, including complex formulations, with a diverse portfolio and global presence.
Strategic Collaborations and Partnerships
Kindeva has engaged in several strategic collaborations:
- Meridian Medical Technologies: Merged in December 2022 to enhance capabilities in autoinjector technology.
- iPharma Labs, Inc.: Acquired in 2022 to strengthen inhalation formulation and development expertise.
- Summit Biosciences: Acquired in January 2024 to add intranasal drug delivery capabilities.
Operational Insights
Kindeva's strategic considerations include:
- Major Competitors: Catalent and Lonza, with their extensive service offerings and global reach.
- Market Position: A leading position in drug-device combination products, bolstered by recent mergers and acquisitions.
- Competitive Advantages: Comprehensive service offerings, extensive patent portfolio, and a strong legacy of innovation.
Strategic Opportunities and Future Directions
Kindeva's strategic roadmap includes:
- Expansion of Capabilities: Enhancing aseptic fill-finish and intranasal drug delivery capabilities.
- Sustainability Initiatives: Developing low-GWP inhalers and green propellant technologies.
- Market Expansion: Leveraging recent acquisitions to enter new therapeutic areas and markets.
Contact Information
- Website: www.kindevadd.com
- Social Media: LinkedIn
